Orchid Pharma Limited Announces Results for FY 2026 and Approves Internal Audit for 2026-27
Orchid Pharma Limited announced on May 25, 2026, that its Board of Directors convened a meeting to review and approve the audited standalone and consolidated financial results for the quarter and full financial year ended March 31, 2026. The board also approved the appointment of the Internal Auditor for the Financial Year 2026-27.Financial Performance for the Year Ended March 31, 2026
The company's financial performance data for the year ended March 31, 2026, reveal key movements across the three major financial statements. All amounts are stated in lakhs of Indian Rupees.Statement of Profit and Loss Summary
The company recorded Total Income of 94,940.06 lakh for the year ended March 31, 2026. Total Expenses were 85,383.58 lakh. Profit before tax stood at 10,648.34 lakh.
A comparison of the key income items (in lakhs) is provided below:
| Particulars | Year Ended Mar 31, 2026 (Audited) | Year Ended Mar 31, 2025 (Audited) |
|---|---|---|
| Net Sales / Income from operations | 81,132.73 | 92,192.59 |
| Total Income | 84,650.06 | 95,385.50 |
| Total Expenses | 81,478.78 | 84,737.16 |
| Profit I before tax | 10,648.34 | 5,178.14 |
| Total comprehensive income (Loss) | 10,573.21 | 4,610.48 |
Balance Sheet Highlights (as at March 31, 2026)
The consolidated Statement of Assets and Liabilities shows the following totals (in lakhs):
| Statement of Assets and Liabilities | As at March 31, 2026 (Consolidated) | As at March 31, 2025 (Consolidated) |
|---|---|---|
| Total non-current assets | 1,22,701.23 | 88,049.74 |
| Total current assets | 68,389.86 | 80,741.73 |
| TOTAL EQUITY AND LIABILITIES | 1,91,091.09 | 1,68,791.47 |
Cash Flow From Operations
For the year ended March 31, 2026, the net cash from operating activities was 9,851.27 lakh. This compared to 2,015.25 lakh in the previous year.
Operational and Strategic Updates
The company provided several updates regarding its operational standing and strategic initiatives:- Global Ownership: Orchid Pharma Limited confirmed it now possesses 100% global ownership of Enmetazobactam (International Brand Name known as EXBLIFEP) (known as Orblicef in India), consolidating rights and control previously split across entities. This marks the full repatriation of the first novel antibiotic molecule discovered in India.
- Acquisitions: The company successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH, Germany, on October 29, 2025, and Allecra Therapeutics SAS, France, on August 01, 2025.
- Subsidiary Acquisition: Orchid Pharma Limited acquired 100% Share Capital of Weilchensee 1272. V V GmbH, a company incorporated under the laws of Germany. This subsidiary was renamed as Orchid Pharma Europe GmbH effective July 30, 2025.
- Amalgamation: The company also reported that it filed a petition with the Hon'ble National Company Law Tribunal, Chennai bench, for the amalgamation of its Holding Company Dhanuka laboratories Limited with Orchid Pharma Limited. The matter was heard on March 18, 2026, and the order remains awaited.
Governance and Audit Appointments
In addition to the financial reports, the board of directors approved the appointment of Mis. T R Chadha & Co. LLP as the Internal Auditor of the Company for the Financial Year 2026-27.Financial Reporting Detail Tables
Statement of Assets and Liabilities (Consolidated - in lakhs)| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| Total non-current assets | 1,22,701.23 | 88,049.74 |
| Total current assets | 68,389.86 | 80,741.73 |
| TOTAL EQUITY AND LIABILITIES | 1,91,091.09 | 1,68,791.47 |
Statement of Cash Flows (Consolidated - in lakhs)
| Activity | Year Ended March 31, 2026 | Year Ended March 31, 2025 |
|---|---|---|
| Cash generated from operations | 9,851.27 | 2,015.25 |
| Net cash used in investing activities | (28,527.44) | (2,693.09) |
| Net cash from (used in) financing activities | 16,998.03 | 2,522.17 |
| Net increase in cash and cash equivalents | (1,409.88) | 1,750.59 |
***
Note: The statutory auditors expressed an unmodified opinion on the audited Standalone results, while the consolidated results included a qualified opinion.
ORCHPHARMA Stock Price Movement
Today, Orchid Pharma Limited shares edged higher to close at ₹715.35, marking a gain of 1.54% for the day. The stock saw strong institutional interest, with trading volumes hitting 81,450 shares in the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: